← Back to Search

Local Anesthetic

Epidural Bupivacaine for Labor Pain

Phase 4
Recruiting
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
Any contraindication to the administration of an epidural technique
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights

Summary

This trial found that the ED90 of bupivacaine via the epidural technique is 3.65 milligrams in women undergoing labor after receiving a lidocaine test dose.

Who is the study for?
This trial is for women in labor at term (37-42 weeks) with a single baby positioned head down, who want epidural pain relief and have moderate to severe pain. They should be less than 5 cm dilated and without major health issues or conditions that increase the risk of cesarean delivery.Check my eligibility
What is being tested?
The study aims to find the right dose of bupivacaine, an anesthetic drug given through the back into the epidural space, which can effectively reduce labor pain in 90% of patients after they've had a lidocaine test dose.See study design
What are the potential side effects?
Possible side effects include discomfort at injection site, lower blood pressure, numbness or weakness in legs, headache from leakage of spinal fluid (rare), and rarely nerve damage.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot have an epidural due to health reasons.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Dural Puncture Epidural TechniqueExperimental Treatment1 Intervention
Laboring women receiving the Dural Puncture Epidural (DPE) Technique, after a lidocaine "test dose", with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
Group II: Epidural TechniqueActive Control1 Intervention
Laboring women receiving the Conventional Epidural Technique (EPL), after receiving a lidocaine "test dose" with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine Hydrochloride
2020
Completed Phase 4
~1420

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,628 Previous Clinical Trials
11,474,520 Total Patients Enrolled
3 Trials studying Labor Pain
340 Patients Enrolled for Labor Pain

Media Library

Bupivacaine Hydrochloride (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT05543694 — Phase 4
Labor Pain Research Study Groups: Dural Puncture Epidural Technique, Epidural Technique
Labor Pain Clinical Trial 2023: Bupivacaine Hydrochloride Highlights & Side Effects. Trial Name: NCT05543694 — Phase 4
Bupivacaine Hydrochloride (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05543694 — Phase 4
~10 spots leftby Oct 2024